neuroone medical technologies corporation operates as a medical technology company. it focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (ceeg) and stereoelectroencephalography (seeg) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, parkinson's disease, dystonia, essential tremors, and other related brain related disorders. the company is based in eden prairie, minnesota.
Company profile
Ticker
NMTC
Exchange
Website
CEO
David A. Rosa
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Original Source Entertainment, Inc.
SEC CIK
Corporate docs
IRS number
270863354
NMTC stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Jul 24
8-K
Material Modifications to Rights of Security Holders
21 Jun 24
S-3
Shelf registration
31 May 24
10-Q
2024 Q2
Quarterly report
14 May 24
8-K
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14 May 24
8-K
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
26 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Mar 24
8-K
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
13 Feb 24
10-Q
2024 Q1
Quarterly report
13 Feb 24
S-8
Registration of securities for employees
31 Jan 24
Transcripts
NMTC
Earnings call transcript
2024 Q2
14 May 24
NMTC
Earnings call transcript
2024 Q1
13 Feb 24
NMTC
Earnings call transcript
2023 Q4
14 Dec 23
NMTC
Earnings call transcript
2023 Q3
14 Aug 23
NMTC
Earnings call transcript
2023 Q3
14 Aug 23
NMTC
Earnings call transcript
2023 Q2
11 May 23
NMTC
Earnings call transcript
2023 Q1
14 Feb 23
NMTC
Earnings call transcript
2022 Q4
13 Dec 22
NMTC
Earnings call transcript
2022 Q3
14 Aug 22
NMTC
Earnings call transcript
2022 Q2
14 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm | 2.43 mm |
Cash burn (monthly) | 82.11 k | 97.29 k | 962.03 k | 1.08 mm | 725.05 k | 985.64 k |
Cash used (since last report) | 317.46 k | 376.16 k | 3.72 mm | 4.17 mm | 2.80 mm | 3.81 mm |
Cash remaining | 2.12 mm | 2.06 mm | -1.28 mm | -1.74 mm | -368.60 k | -1.38 mm |
Runway (months of cash) | 25.8 | 21.2 | -1.3 | -1.6 | -0.5 | -1.4 |
Institutional ownership, Q1 2024
8.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 22.60 mm |
Total shares | 2.39 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Manchester Management | 2.36 mm | $2.39 mm |
Princeton Global Asset Management | 16.83 k | $20.20 mm |
Centerpoint Advisors | 5.00 k | $6.00 k |
Simplex Trading | 1.72 k | $2.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun 24 | Christianson Mark | Common Stock | Payment of exercise | Dispose F | No | No | 0.8 | 343 | 274.40 | 294,692 |
30 Jun 24 | Rosa David A | Common Stock | Payment of exercise | Dispose F | No | No | 0.8 | 4,697 | 3.76 k | 1,155,661 |
30 Jun 24 | Steve Mertens | Common Stock | Payment of exercise | Dispose F | No | No | 0.8 | 1,158 | 926.40 | 174,999 |
6 Jun 24 | Christianson Mark | Common Stock | Sell | Dispose S | No | No | 0.876 | 2,189 | 1.92 k | 295,035 |
5 Jun 24 | Christianson Mark | Common Stock | Sell | Dispose S | No | No | 0.8784 | 25,800 | 22.66 k | 297,224 |
Press releases
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
20 Jun 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14 May 24
NeuroOne® to Report Second Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on May 14
10 May 24